Sunesis Pharmaceuticals (SNSS) Provides Updated Data from Vosaroxin Phase 1b/2 in AML
Tweet Send to a Friend
Sunesis Pharmaceuticals (Nasdaq: SNSS) announced the presentation of updated results from an ongoing Phase 1b/2 University of Texas MD Anderson ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
